4528:TYO
Ono Pharmaceutical Co Ltd
Â¥2,472.00
arrow_downward
-0.58%(-14.50) 1D
Nov 13, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4528...
Open
Â¥2,473
High
Â¥2,489
Low
Â¥2,446
Mkt. cap
1.23T
Avg. vol.
1.97M
Volume
1.20M
Dividend
3.24%
Quarterly dividend
Â¥20
Ex-dividend date
Mar 30, 2027
P/E ratio
15.57
52-wk high
Â¥2,674
52-wk low
Â¥1,982
EPS
Â¥159
Shares outstanding
514.12M
No. of employees
4K
Open
Â¥2,473
High
Â¥2,489
Low
Â¥2,446
Mkt. cap
1.23T
Avg. vol.
1.97M
Volume
1.20M
Dividend
3.24%
Quarterly dividend
Â¥20
Ex-dividend date
Mar 30, 2027
P/E ratio
15.57
52-wk high
Â¥2,674
52-wk low
Â¥1,982
EPS
Â¥159
Shares outstanding
514.12M
No. of employees
4K
News stories
From web sources and news partners
Yahoo Finance
·
22 hours ago
Stock market today: Dow, S&P 500, Nasdaq futures edge higher after wholesale inflation grows, Nvidia stock rebounds
CNBC
·
1 day ago
Nasdaq Composite slides as Nvidia shares tumble on Jensen Huang’s exit; oil prices jump
MarketWatch
·
13 hours ago
Stock Market on Nov. 13, 2026: Dow ends slightly higher, S&P 500 and Nasdaq fall as tech stocks struggle after Nvidia turmoil; U.S. equities market books weekly gain — live updates
Foreign Policy Journal
·
30 minutes ago
Narrowing Valuation Gap Between Booking Holdings (NASDAQ: BKNG) And GameStop (NYSE: GME) Masks A Clear Winner For 2027
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4.21K
Founded1717
HeadquartersOsaka, Osaka, Japan
SectorHealth Care
IndustryPharmaceutical industry
Websiteono-pharma.com